Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval
- University of Edinburgh
- Scotland
- Selective procedure
- 7 November 2025 to 7 November 2028
Production starts with a 30L unconcentrated LVV-containing harvest from 293T cells using a certified Master Cell Bank and supplied genome and packaging plasmids, then concentrates the supernatant approximately 100–200×. Includes comprehensive GMP-compliant quality control, quality warranties and replacement for spoilage. The bidder must be the manufacturing entity, although quality control may be subcontracted.
- Awarded value
- Not published
- Published
- 30 July 2025
- Contract length
- 36 months
- Ends 7 November 2028